Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Maze Therapeutics (NASDAQ: MAZE ) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from the same period last year.